CCEL — Cryo-Cell International Balance Sheet
0.000.00%
- $36.68m
- $40.67m
- $31.99m
- 79
- 97
- 68
- 96
Annual balance sheet for Cryo-Cell International, fiscal year end - November 30th, USD millions except per share, conversion factor applied.
2020 November 30th | 2021 November 30th | 2022 November 30th | 2023 November 30th | 2024 November 30th | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 10.4 | 8.34 | 1.72 | 0.98 | 3.5 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 6.32 | 5.25 | 6.04 | 6.58 | 7.31 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 18.6 | 15.8 | 9.61 | 9.45 | 12.6 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1.94 | 4.15 | 14.2 | 22 | 22.7 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 46.2 | 60.7 | 64.9 | 61.2 | 64.7 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 16.4 | 21.1 | 19.5 | 20.9 | 21.6 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 48.9 | 56.5 | 66.4 | 72.3 | 77.9 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Total Equity | -2.67 | 4.18 | -1.52 | -11 | -13.2 |
| Total Liabilities & Shareholders' Equity | 46.2 | 60.7 | 64.9 | 61.2 | 64.7 |
| Total Common Shares Outstanding |